Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joanne Mortimer

Showing results (61-70 of 110) with videos related to

Pageof 11
Sort By:
Journal of Cancer Survivorship : Research and Practice|July 19, 2020
Hispanic ethnicity as a moderator of the effects of aerobic and resistance exercise on physical fitness and quality-of-life in breast cancer survivorsChristina M Dieli-Conwright, Frank S Fox, Debu Tripathy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancerDavid P Kelsen, Katryn A Winter, Leonard L Gunderson, et al.
The Oncologist|August 6, 2021
Recall of Genomic Testing Results Among Patients with CancerSam E Wing, Hengrui Hu, Lisa Lopez, et al.
Plos One|November 7, 2019
Mutation and immune profiling of metaplastic breast cancer: Correlation with survivalMichelle Afkhami, Daniel Schmolze, Susan E Yost, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2017
Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR<sup>+</sup>/HER2<sup>+</sup> Breast Cancer Patient-Derived Xenografts to Trastuzumab or FulvestrantPei-Yin Hsu, Victoria Shang Wu, Noriko Kanaya, et al.
Journal of Hematology & Oncology|February 7, 2025
Pharmacological activity of OST-01, a natural product from baccharis coridifolia, on breast cancer cellsHyunJun Kang, Dinh Hoa Hoang, Melissa Valerio, et al.
The Oncologist|December 11, 2014
Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional ageArti Hurria, M Suzette Blanchard, Timothy W Synold, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 2, 2023
Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-<sup>18</sup>F-Fluoro-17β-FluoroestradiolGary A Ulaner, David A Mankoff, Amy S Clark, et al.
Oncotarget|July 3, 2018
ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancerKarineh Petrossian, Noriko Kanaya, Chiao Lo, et al.
Cancer|December 14, 2022
Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancerSayeh M Lavasani, George Somlo, Susan E Yost, et al.
Pageof 11

Showing results (61-70 of 110) with videos related to

Sort By:
Pageof 11
Journal of Cancer Survivorship : Research and Practice|July 19, 2020
Hispanic ethnicity as a moderator of the effects of aerobic and resistance exercise on physical fitness and quality-of-life in breast cancer survivorsChristina M Dieli-Conwright, Frank S Fox, Debu Tripathy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancerDavid P Kelsen, Katryn A Winter, Leonard L Gunderson, et al.
The Oncologist|August 6, 2021
Recall of Genomic Testing Results Among Patients with CancerSam E Wing, Hengrui Hu, Lisa Lopez, et al.
Plos One|November 7, 2019
Mutation and immune profiling of metaplastic breast cancer: Correlation with survivalMichelle Afkhami, Daniel Schmolze, Susan E Yost, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2017
Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR<sup>+</sup>/HER2<sup>+</sup> Breast Cancer Patient-Derived Xenografts to Trastuzumab or FulvestrantPei-Yin Hsu, Victoria Shang Wu, Noriko Kanaya, et al.
Journal of Hematology & Oncology|February 7, 2025
Pharmacological activity of OST-01, a natural product from baccharis coridifolia, on breast cancer cellsHyunJun Kang, Dinh Hoa Hoang, Melissa Valerio, et al.
The Oncologist|December 11, 2014
Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional ageArti Hurria, M Suzette Blanchard, Timothy W Synold, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 2, 2023
Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-<sup>18</sup>F-Fluoro-17β-FluoroestradiolGary A Ulaner, David A Mankoff, Amy S Clark, et al.
Oncotarget|July 3, 2018
ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancerKarineh Petrossian, Noriko Kanaya, Chiao Lo, et al.
Cancer|December 14, 2022
Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancerSayeh M Lavasani, George Somlo, Susan E Yost, et al.
Pageof 11